Patricia M. Danzon

Patricia Danzon is the Celia Moh Professor Emeritus at The Wharton School, University of Pennsylvania. She received a B.A. from Oxford University, England, and a Ph.D. in Economics from the University of Chicago. Professor Danzon is an internationally recognized expert in the economics of health care, the biopharmaceutical industry, and insurance. She is a member of the National Academy of Medicine and a former Research Associate at the National Bureau of Economic Research. She has served as a consultant to many governmental agencies, NGOs and private corporations in the US and internationally. Professor Danzon has been an Associate Editor of the American Economic Review, the Journal of Health Economics and the International Journal of Health Care Finance and Economics. She has published widely in scholarly journals on a broad range of subjects related to health care, pharmaceuticals, biotechnology, insurance, and the economics of law.

Why the FTC Should Consider Size in Drug Mergers

Large pharmaceutical firms retain their dominance through size-related advantages in three areas: contracting, marketing and selling, and financing. When reviewing pharmaceutical mergers,...

Latest news

International Policymaking Must Evolve

In this Q&A about his new book for ProMarket, Paul Tucker explains the changing global order and the need for academics, policymakers...

Capitalism Does Not Require a Tradeoff Between Planet and Profit

Critics of capitalism claim that the economic system incorrigibly encourages the exploitation of the planet and is thus incompatible with efforts to...

Academic Bias Under the Microscope

That scholarship often reflects conscious and unconscious biases has long been an open secret in academia. On April 22, Professors Christian Leuz,...

Corporations Are Not “We the People”

The Citizens United ruling contradicts the Founders, decades of Supreme Court precedent and the will of the American people.

Too Many Economists Are Using a Flawed Theory To Defend Dominant Platforms’ Self-Preferencing Practices

Congress is currently considering two major bills that would regulate “self-preferencing” and related conduct by dominant digital platforms. Criticism of these bills...

Unfair Methods of Competition

The FTC’s new policy on unfair methods of competition is an assertion of the original purpose of the agency, allowing it to...

Event Notes: Whose Business is Health?

On Oct.14, the Hopkins Business of Health Initiative hosted a panel discussing if and how companies should consider the health implications of...